Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
作者信息
Lee Sung Hwan, Yim Sun Young, Kim Ji Hoon, Lee Sunyoung S, Kaseb Ahmed O, Wei Peng, Lee Ju-Seog
机构信息
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
Abstract
摘要
相似文献
1
Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".致编辑的信：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
2
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".致关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论1的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
3
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".致关于“基因组生物标志物预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应：来自IMbrave150试验的见解”的编辑评论2
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
4
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".对关于“预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信的回复
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
5
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
6
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".预测晚期肝细胞癌组织中联合免疫治疗反应的转录组特征：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):308-310. doi: 10.3350/cmh.2024.0726. Epub 2024 Aug 30.
7
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
8
Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823].《肝细胞癌中预测阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解》勘误 [《临床分子肝病学》2024年；30:807 - 823]
Clin Mol Hepatol. 2025 Apr;31(2):669-670. doi: 10.3350/cmh.2024.0333e. Epub 2025 Feb 27.
9
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.阿替利珠单抗联合贝伐单抗用于不符合IMbrave150纳入标准的不可切除肝细胞癌患者的早期反应及安全性
Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.
10
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
本文引用的文献
1
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.用于预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的转录组生物标志物的综合分析
Clin Mol Hepatol. 2025 Jan;31(1):e31-e34. doi: 10.3350/cmh.2024.0628. Epub 2024 Sep 20.
2
Emerging methods and techniques for cancer biomarker discovery.癌症生物标志物发现的新兴方法和技术。
Pathol Res Pract. 2024 Oct;262:155567. doi: 10.1016/j.prp.2024.155567. Epub 2024 Aug 29.
3
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
4
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.晚期肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗的临床反应和耐药的分子相关性。
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.T 细胞功能障碍和耗竭的特征可预测癌症免疫疗法的反应。
Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.
7
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.生物标志物开发以及药物与生物标志物共同开发中的挑战与问题透视
J Natl Cancer Inst. 2009 Nov 4;101(21):1453-63. doi: 10.1093/jnci/djp334. Epub 2009 Oct 23.
8
The cancer biomarker problem.癌症生物标志物问题。
Nature. 2008 Apr 3;452(7187):548-52. doi: 10.1038/nature06913.
9
Evaluating the yield of medical tests.评估医学检查的收益。
JAMA. 1982 May 14;247(18):2543-6.
Zotero 插件